货号:A724317
同义名:
GArdiquimod trifluoroacetate
Gardiquimod trifluoroacetate is a specific TLR7 agonist.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Immune response modifiers are being studied as therapeutic agents for viral infections and cancer. These molecules include agonists for the Toll-like receptors (TLR), a family of innate immune receptors. TLR7 and 8, located in cellular endosomes, bind single-stranded RNA characteristic of viral genomes, and trigger intracellular signaling pathways that induce inflammatory cytokines and antiviral innate immune factors[1]. Gardiquimod trifluoroacetate is a specific TLR7 agonist when used at concentrations below 10 μM, which can also inhibit HIV-1 reverse transcriptase[1]. Levels of HIV-1 DNA are significantly lower in Gardiquimod trifluoroacetate-treated cells compared to untreated controls on day 9 postinfection. Significantly lower levels of HIV-1 DNA and HIV-1 p24 are observed in Gardiquimod trifluoroacetate-treated and HIV-1-exposed macrophages cocultured with activated peripheral blood mononuclear cells (PBMCs). Gardiquimod trifluoroacetate significantly increased IFN-α mRNA levels 80-, 20-, and 35-fold above the level of detection at 2, 4, and 6 h post treatment, respectively[1]. Gardiquimod, added prior to or within 2 days after infection with X4, R5, or dual-tropic (R5/X4) strains of HIV-1, significantly reduced infection in macrophages and activated PBMCs. Cocultures of activated PBMCs added to gardiquimod-treated and HIV-1-exposed macrophages demonstrated minimal HIV-1 replication for up to 10 days, suggesting that gardiquimod inhibited activated PBMCs viral amplification from HIV-1-exposed macrophages. Gardiquimod treatment of both activated PBMCs and macrophages induced interferon-alpha (IFN-α) transcription within hours of addition, and sustained IFN-α protein secretion for several days[1]. On day 12, the tumor volume in mice injected with PBS increased to 1770 ± 370 mm3, whereas it was only 230 ± 70 mm3 in mice treated with Gardiquimod trifluoroacetate[2]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.85mL 0.37mL 0.18mL |
9.23mL 1.85mL 0.92mL |
18.47mL 3.69mL 1.85mL |
CAS号 | 1159840-61-5 |
分子式 | C21H25F6N5O5 |
分子量 | 541.44 |
SMILES Code | CC(O)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F |
MDL No. | MFCD31619251 |
别名 | GArdiquimod trifluoroacetate |
运输 | 蓝冰 |
InChI Key | XFQPQSJDMJVOBN-UHFFFAOYSA-N |
Pubchem ID | 44592365 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere, room temperature |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|